On April 7, 2023, the district court granted a preliminary injunction and stayed the FDA’s approval of mifepristone. [5] The Supreme Court, in fact, affirmed the authority of the FDA with regard to mifepristone as recently as 2021. On April 7, 2023, Judge Kacsmaryk granted in part the plaintiffs’ request for a preliminary injunction, staying the FDA’s various approvals of mifepristone. [32]The District Court rejected the government’s jurisdictional and procedural objections to the lawsuit. Instead, the District Court held that plaintiff medical associations have both associational standing and organizational standing to bring suit.

Source: New York Times April 13, 2023 01:38 UTC